Gene: IFI30

10437
GILT|IFI-30|IP-30|IP30
IFI30, lysosomal thiol reductase
protein-coding
19p13.11
Ensembl:ENSG00000216490 MIM:604664 Vega:OTTHUMG00000183373 UniprotKB:P13284
NC_000019.10
PubMed
0   ANCO-SNPs
ND
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
6.628e-1 (AD)  1.527e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
TYMP0.938
SPI10.933
S100A110.922
LCP10.921
FCER1G0.921
HCK0.907
CD300A0.907
ABI30.907
CD140.905
PTPN60.904

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
MARCH4-0.521
KCNIP3-0.516
NEUROD6-0.505
SLC7A4-0.504
ABCC12-0.493
TMEM179-0.493
EXTL1-0.49
WNT7A-0.482
ADRA1D-0.479
CPLX3-0.474

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0512461-methylanthracene[1-methylanthracene co-treated with fluoranthene] results in decreased expression of IFI30 mRNA28329830
C5486512-(1'H-indolo-3'-carbonyl)thiazole-4-carboxylic acid methyl ester2-(1'H-indolo-3'-carbonyl)thiazole-4-carboxylic acid methyl ester results in increased expression of IFI30 mRNA19933214
C0109142,4-diaminotoluene"2,4-diaminotoluene results in increased expression of IFI30 mRNA"20713471
C0235142,6-dinitrotoluene"2,6-dinitrotoluene affects the expression of IFI30 mRNA"21346803
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFI30 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFI30 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFI30 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFI30 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFI30 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFI30 mRNA"27188386
D000447AldehydesAldehydes results in increased expression of IFI30 mRNA25014914
D018501Antirheumatic AgentsAntirheumatic Agents results in decreased expression of IFI30 mRNA24449571
D001241AspirinAspirin results in decreased expression of IFI30 mRNA15928584
D001280AtrazineAtrazine results in increased expression of IFI30 mRNA22378314
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of IFI30 mRNA19152381|2010694
D001564Benzo(a)pyrenechlorophyllin inhibits the reaction [Benzo(a)pyrene results in increased expression of IFI30 mRNA]19152381
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of IFI30 mRNA22228805
C006780bisphenol Abisphenol A results in increased expression of IFI30 mRNA15223131
C006780bisphenol Abisphenol A affects the expression of IFI30 mRNA25181051
C000611646bisphenol F[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of IFI30 mRNA28628672
C018475butyraldehydebutyraldehyde results in increased expression of IFI30 mRNA26079696
D002104CadmiumCadmium results in increased expression of IFI30 mRNA24376830
D019256Cadmium ChlorideCadmium Chloride results in increased expression of IFI30 mRNA23741332
D019256Cadmium ChlorideCadmium Chloride results in increased methylation of IFI30 promoter22457795
C007020chlorophyllinchlorophyllin inhibits the reaction [Benzo(a)pyrene results in increased expression of IFI30 mRNA]19152381
D004390ChlorpyrifosChlorpyrifos results in decreased expression of IFI30 mRNA21356183
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of IFI30 mRNA20938992
C018021cobaltous chloridecobaltous chloride results in decreased expression of IFI30 mRNA24612858
D003300Copper[NSC 689534 binds to Copper] which results in decreased expression of IFI30 mRNA20971185
D019327Copper SulfateCopper Sulfate results in decreased expression of IFI30 mRNA19549813
D003471CuprizoneCuprizone results in increased expression of IFI30 mRNA27523638
D016572CyclosporineCyclosporine results in decreased expression of IFI30 mRNA20106945|2556210
C014347decitabine[decitabine co-treated with vorinostat] affects the expression of IFI30 mRNA17330099
D003907DexamethasoneDexamethasone inhibits the reaction [RX3 gene mutant form affects the expression of IFI30 mRNA]27941970
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of IFI30 mRNA28628672
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of IFI30 mRNA28628672
D003907DexamethasoneDexamethasone results in increased expression of IFI30 mRNA22733784
D003993Dibutyl PhthalateDibutyl Phthalate results in decreased expression of IFI30 mRNA21266533
D002945Cisplatin[Cisplatin co-treated with jinfukang] results in increased expression of IFI30 mRNA27392435
D002945CisplatinCisplatin results in increased expression of IFI30 mRNA27392435|2759478
D002945CisplatinIFI30 protein affects the susceptibility to Cisplatin16217747
D004041Dietary FatsDietary Fats results in decreased expression of IFI30 mRNA18042831
D004041Dietary FatsDietary Fats results in increased expression of IFI30 mRNA22609946
C118739entinostatentinostat results in increased expression of IFI30 mRNA26272509|2718838
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFI30 mRNA"27188386
D004785Environmental PollutantsEnvironmental Pollutants results in decreased expression of IFI30 mRNA24534155
D004997Ethinyl EstradiolEthinyl Estradiol affects the expression of IFI30 mRNA17555576
D004997Ethinyl EstradiolEthinyl Estradiol results in increased expression of IFI30 mRNA12072388
C540355fenamidonefenamidone results in increased expression of IFI30 mRNA27029645
C007738fluoranthene[1-methylanthracene co-treated with fluoranthene] results in decreased expression of IFI30 mRNA28329830
D005492Folic Acid[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IFI30 mRNA22975265
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of IFI30 mRNA20938992
C069837fullerene C60fullerene C60 results in decreased expression of IFI30 mRNA19167457
D005839GentamicinsGentamicins results in increased expression of IFI30 mRNA22061828
D017313FenretinideFenretinide results in increased expression of IFI30 mRNA28973697
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of IFI30 mRNA28628672
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of IFI30 mRNA28628672
D007213IndomethacinIndomethacin results in increased expression of IFI30 mRNA28201806
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of IFI30 mRNA28628672
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of IFI30 mRNA28628672
D007559IvermectinIvermectin results in increased expression of IFI30 mRNA26443706
C544151jinfukang[Cisplatin co-treated with jinfukang] results in increased expression of IFI30 mRNA27392435
C544151jinfukangjinfukang results in increased expression of IFI30 mRNA27392435
C410337K 7174K 7174 results in decreased expression of IFI30 mRNA24086573
D008154LucanthoneLucanthone results in increased expression of IFI30 mRNA21148553
D008627Mercuric ChlorideMercuric Chloride affects the expression of IFI30 mRNA20353558
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of IFI30 mRNA20938992
D018817N-Methyl-3,4-methylenedioxyamphetamine"N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of IFI30 mRNA"20188158
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in increased expression of IFI30 mRNA"25554681
D037742Nanotubes, Carbon"Nanotubes, Carbon results in increased expression of IFI30 mRNA"25554681|2710602
C017096n-butoxyethanoln-butoxyethanol results in decreased expression of IFI30 mRNA19812364
D009532NickelNickel results in increased expression of IFI30 mRNA25583101
C022838nickel chloridenickel chloride results in decreased expression of IFI30 mRNA24612858
C029938nickel sulfatenickel sulfate results in increased expression of IFI30 mRNA22714537
C558013NSC 689534[NSC 689534 binds to Copper] which results in decreased expression of IFI30 mRNA20971185
D017239PaclitaxelIFI30 mRNA results in decreased susceptibility to Paclitaxel16322897
D000073878Palm OilPalm Oil results in decreased expression of IFI30 mRNA18042831
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFI30 mRNA"27188386
C496932panobinostatpanobinostat results in increased expression of IFI30 mRNA26272509
D000068437Pemetrexed[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IFI30 mRNA22975265
C046012pentanalpentanal results in increased expression of IFI30 mRNA26079696
C031181phenanthrenephenanthrene results in decreased expression of IFI30 mRNA19457238
D010634PhenobarbitalPhenobarbital affects the expression of IFI30 mRNA19159669
C006253pirinixic acidpirinixic acid results in increased expression of IFI30 mRNA23811191
D011078Polychlorinated BiphenylsPolychlorinated Biphenyls affects the expression of IFI30 mRNA21334430
C005556propionaldehydepropionaldehyde results in increased expression of IFI30 mRNA26079696
C513428pyrachlostrobinpyrachlostrobin results in increased expression of IFI30 mRNA27029645
D011794QuercetinQuercetin results in increased expression of IFI30 mRNA21632981
C059514resveratrolresveratrol results in increased expression of IFI30 mRNA25888808
C513635S-2-pentyl-4-pentynoic hydroxamic acidS-2-pentyl-4-pentynoic hydroxamic acid results in increased expression of IFI30 mRNA21427059
D012822Silicon DioxideSilicon Dioxide results in increased expression of IFI30 mRNA22431001
C017947sodium arsenitesodium arsenite affects the expression of IFI30 mRNA20816728
C017947sodium arsenitesodium arsenite results in increased expression of IFI30 mRNA16322246
C016104sodium bichromatesodium bichromate results in decreased expression of IFI30 mRNA17685462
C016766sulforafansulforafan results in increased expression of IFI30 mRNA26833863
D013629TamoxifenTamoxifen affects the expression of IFI30 mRNA17555576
C010792testosterone undecanoatetestosterone undecanoate results in increased expression of IFI30 mRNA19074003
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of IFI30 mRNA20106945|2163298
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of IFI30 mRNA21570461
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of IFI30 mRNA19933214
D013853ThioacetamideThioacetamide results in increased expression of IFI30 mRNA23411599
C052342topiramate[topiramate co-treated with Trinitrobenzenesulfonic Acid] results in decreased expression of IFI30 mRNA21849664
D014212TretinoinTretinoin results in increased expression of IFI30 mRNA15894607
C012589trichostatin Atrichostatin A results in increased expression of IFI30 mRNA15901671
C012589trichostatin Atrichostatin A affects the expression of IFI30 mRNA28542535
D014302Trinitrobenzenesulfonic Acid[topiramate co-treated with Trinitrobenzenesulfonic Acid] results in decreased expression of IFI30 mRNA21849664
C016805tris(1,3-dichloro-2-propyl)phosphate"tris(1,3-dichloro-2-propyl)phosphate results in decreased expression of IFI30 mRNA"26179874
D014635Valproic AcidValproic Acid results in increased expression of IFI30 mRNA15901671
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFI30 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of IFI30 mRNA25979313
D014635Valproic AcidValproic Acid results in decreased expression of IFI30 mRNA29154799
D014635Valproic AcidValproic Acid results in increased expression of IFI30 mRNA19101580|2317975
D014635Valproic AcidValproic Acid results in increased expression of IFI30 mRNA20546886|2142705
C025643vinclozolinvinclozolin results in decreased expression of IFI30 mRNA23034163
C029297vinylidene chloridevinylidene chloride results in increased expression of IFI30 mRNA26682919
D024483Vitamin K 3Vitamin K 3 affects the expression of IFI30 mRNA20044591
C111237vorinostat[decitabine co-treated with vorinostat] affects the expression of IFI30 mRNA17330099

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005515protein binding-IPI25416956  
GO:0016667oxidoreductase activity, acting on a sulfur group of donors-EXP10639150  17142755  
GO:0016667oxidoreductase activity, acting on a sulfur group of donors-IMP10639150  
GO ID GO Term Qualifier Evidence PubMed
GO:0019886antigen processing and presentation of exogenous peptide antigen via MHC class II-TAS-  
GO:0042590antigen processing and presentation of exogenous peptide antigen via MHC class I-ISS-  
GO:0055114oxidation-reduction process-IEA-  
GO:0060333interferon-gamma-mediated signaling pathway-TAS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005576extracellular region-IEA-  
GO:0005764lysosome-IDA10639150  
GO:0005829cytosol-IDA-  
GO:0030054cell junction-IDA-  
GO:0043202lysosomal lumen-TAS-  
GO:0043231intracellular membrane-bounded organelle-IDA-  
KEGG ID KEGG Term
hsa04612Antigen processing and presentation
Reactome ID Reactome Term Evidence
R-HSA-1280215Cytokine Signaling in Immune systemTAS
R-HSA-1280218Adaptive Immune SystemTAS
R-HSA-168256Immune SystemTAS
R-HSA-2132295MHC class II antigen presentationTAS
R-HSA-877300Interferon gamma signalingTAS
R-HSA-913531Interferon SignalingTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
22178353Genetic contribution to C-reactive protein levels in severe obesity. (2012 Mar)Faucher GMol Genet Metab